Advanced Follicular Lymphoma
Conditions
Brief summary
This open-label, single arm study will evaluate the safety of obinutuzumab administered as a short duration infusion (SDI; target 90-minute infusion) during cycle 2 and from cycle 2 onwards in combination with chemotherapy in participants with previously untreated advanced follicular lymphoma (FL). The study has two phases: in the first phase, participants will receive the first cycle of obinutuzumab-based chemotherapy (G-chemo) induction therapy as usual with the first three infusions of obinutuzumab (1000 mg) administered at the regular infusion rate on Day 1, 8, and 15 of cycle 1. Phase 2 starts when participants who do not experience any Grade ≥ 3 infusion related reactions during the first cycle receive their first obintuzumab infusion given at the faster infusion rate in Cycle 2. For Cycle 2, Day 1 and all other following infusions (including maintenance), obinutuzumab will be administered at a faster infusion of 90-minute SDI, as long as the participant does not experience any Grade ≥ 3 infusion related reactions. The investigator is free to choose the chemotherapy for each participant (bendamustine, CHOP \[cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone/methylprednisolone\], or CVP \[cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone\]). The total number of cycles of G-chemo induction therapy and the cycles length depends on the chemotherapy chosen for each participant.
Interventions
DRUGCyclophosphamide
Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
DRUGDoxorubicin
Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle, for six cycles.
DRUGObinutuzumab
Obinutuzumab 1000 mg IV infusion, administered on Day 1, 8 and 15 during Cycle 1, and on Day 1 of subsequent cycles, for 6-8 cycles. Each cycle is 21 or 28 days long depending on the chemotherapy regimen allocated. Maintenance obinutuzumab monotherapy in patients who achieve at least a partial response, after induction therapy will be administered a dose of 1000 mg once every 8 weeks for 2 years or until disease progression (whichever occurs first).
DRUGBendamustine
Bendamustine will be administered on Days 1 and 2 for Cycles 1-6 at a dose of 90 mg/m2/day, for six 28-day cycles.
DRUGPrednisone/Prednisolone/Methylprednisolone
Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
DRUGVincristine
Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
Sponsors
Hoffmann-La Roche
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with previously untreated Stage III or IV FL or Stage II bulky disease scheduled to receive obinutuzumab plus chemotherapy due to at least one of the following criteria: a.) Bulky disease, defined as a nodal or extranodal (except spleen) mass ≥ 7 cm in the greatest diameter b.) Local symptoms or compromise of normal organ function due to progressive nodal disease or extranodal tumor mass c.) Presence of B symptoms (fever \[\> 38ºC\], drenching night sweats, or unintentional weight loss of \> 10% of normal body weight over a period of 6 months or less) d.) Presence of symptomatic extranodal disease (e.g., pleural effusions, peritoneal ascites) e.) Cytopenias due to underlying lymphoma (i.e., absolute neutrophil count \< 1.0 × 109/L, hemoglobin \< 10 g/dL, and/or platelet count \< 100 × 109/L) f.) Involvement of ≥ 3 nodal sites, each with a diameter of ≥ 3 cm g.) Symptomatic splenic enlargement * Histologically documented CD-20-positive FL, as determined by the local laboratory * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Adequate hematologic function (unless abnormalities are related to FL) * Life expectancy of ≥ 12 months * For women who are not postmenopausal (≥ 12 consecutive months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \< 1% per year during the treatment period and for at least 18 months after the last dose of obinutuzumab, for at least 3 months after the last dose of bendamustine or according to institutional guidelines for CHOP or CVP chemotherapy, whichever is longer * For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm
Exclusion criteria
* Relapsed / refractory FL * Prior treatment for FL with chemotherapy, radiotherapy, or immunotherapy * Grade IIIb FL * Histological evidence of transformation of FL into high-grade B-cell NHL * Treatment with systemic immunosuppressive medications, including, but not limited to, prednisone/prednisolone/methylprednisolone (at a dose equivalent to \>30 mg/day prednisone), azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to Day 1 of Cycle 1 * History of solid organ transplantation * History of anti-CD20 antibody therapy * History of severe allergic or anaphylactic reaction to humanized, chimeric, or murine monoclonal antibodies * Known sensitivity or allergy to murine products * Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any of the study drugs * Active bacterial, viral, fungal, or other infection or any major episode of infection requiring treatment with IV antibiotics within 4 weeks of Day 1 of Cycle 1 * Positive test results for chronic HBV infection (defined as positive HBsAg serology) * Positive test results for hepatitis C (hepatitis C virus \[HCV\] antibody serology testing) * Known history of HIV positive status * History of progressive multifocal leukoencephalopathy (PML) * Vaccination with a live virus vaccine within 28 days prior to Day 1 of Cycle 1 or anticipation that such a live, attenuated vaccine will be required during the study * History of prior other malignancy with the exception of: a. Curatively treated carcinoma in situ of the cervix, good-prognosis ductal carcinoma in situ of the breast, basal- or squamous-cell skin cancer, Stage I melanoma, or low-grade, early-stage localized prostate cancer b. Any previously treated malignancy that has been in remission without treatment for ≥ 2 years prior to enrollment * Evidence of any significant, uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina) or significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm) * Major surgical procedure other than for diagnosis within 28 days prior to Day 1 of Cycle 1, Day 1, or anticipation of a major surgical procedure during the course of the study * Any of the following abnormal laboratory values: 1. Creatinine \> 1.5 × the upper limit of normal (ULN) (unless creatinine clearance normal) or creatinine clearance \< 40 mL/min 2. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.5 × ULN 3. Total bilirubin ≥ 1.5 × the ULN: Patients with documented Gilbert disease may be enrolled if total bilirubin is ≤ 3.0 × the ULN. 4. International normalized ratio (INR) \> 1.5 in the absence of therapeutic anticoagulation 5. Partial thromboplastin time or activated partial thromboplastin time \> 1.5 × ULN in the absence of a lupus anticoagulant * For patients who will be receiving CHOP: left ventricular ejection fraction (LVEF) \< 50% by multigated acquisition (MUGA) scan or echocardiogram * Pregnant or lactating, or intending to become pregnant during the study * Any investigational therapy within 28 days prior to the start of Cycle 1 * Positive test results for human T-lymphotropic virus 1 (HTLV-1)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Grade >=3 Infusion-Related Reactions (IRRs) During Cycle 2 in Patients Who Had Previously Received Obinutuzumab at the Standard Infusion Rate During Cycle 1 Without Experiencing a Grade 3 or 4 IRR | Within 24 hours from the end of study treatment infusion of Day 1 in Cycle 2 (1 cycle: 21 or 28 days depending on the chemotherapy selected) | IRRs were defined as all adverse events (AEs) that occurred during or within 24 hours from the end of study treatment infusion and were judged as related to infusion of study treatment components by the investigator. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of IRRs Regardless of Grade by Cycle | Within 24 hours from the end of study treatment infusion in all cycles, including maintenance ((1 cycle: 21 or 28 days depending on the chemotherapy selected); up to approximately 2.5 years) | IRRs were defined as all adverse events (AEs) that occurred during or within 24 hours from the end of study treatment infusion and were judged as related to infusion of study treatment components by the investigator. |
| Time to IRR From Infusion to Onset of the IRR During Cycle 2 | From infusion to onset of IRR during Cycle 2 (1 cycle: 21 or 28 days depending on the chemotherapy selected) | Time to IRR (of any grade) in Cycle 2 was defined as the time from the start of infusion (i.e., start date/time of infusion of the first component of study treatment) in Cycle 2 to the onset of the IRR (of any grade) during Cycle 2. |
| Duration (In Minutes) of Obinutuzumab Administration by Cycle | All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years) | The duration of obinutuzumab administration (in minutes) by cycle was defined as the difference between the end time and the start time of obinutuzumab administration. |
| Type of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle | All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years) | — |
| Percentage of Participants With Adverse Events (AEs) | Baseline up to end of study (approximately 4 years) | An AE was defined as any untoward medical occurrence in a clinical investigation participant who was administered a pharmaceutical product, regardless of causal attribution. An AE was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study, recurrence of an intermittent medical condition, deterioration in a laboratory value or other clinical test or were related to a protocol-mandated intervention were also considered AEs. Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. |
| Objective Response Rate (ORR) at the End of Induction (EOI) Therapy | Baseline up to end of induction therapy (up to approximately 6 months) | ORR at EOI therapy was defined as the percentage of particpants with either a CR, CR unconfirmed or PR at the EOI visit, as determined by the investigator and according to the guidelines used at the site. |
| Progression-Free Survival (PFS) Rate at the End of the Study | Baseline up to end of study (up to approximately 4 years) | PFS was defined as the time from start of treatment to the first occurrence of disease progression as assessed by the investigator according to the guidelines used at the site or death from any cause. |
| Overall Survival (OS) at the End of the Study | Baseline up to end of study (up to approximately 4 years) | OS was defined as the time from start of treatment (date of first intake of any study treatment component) to death from any cause. |
| Complete Response (CR) Rate at 30 Months (CR30), as Assessed by the Investigator and According to the Guidelines Used at the Site | Baseline up to 30 months | The CR30 rate was defined as the percentage of participants with a CR at 30 months from study treatment initiation (date of first intake of any study treatment component), as determined by the investigator according to the guidelines used at the site. |
| Duration of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle | All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years) | The duration, in minutes, of IRRs during all cycles, where obinutuzumab was administered as an SDI. |
Countries
Brazil, Germany, Japan, Netherlands, Spain, United Kingdom, United States
Participant flow
Recruitment details
Participants were enrolled at 35 sites across 7 countries.
Pre-assignment details
Of the all participants population (114 participants), one participant did not receive the study treatment, thus the safety-evaluable population included 113 participants.
Participants by arm
| Arm | Count |
|---|---|
| All Participants Participants were enrolled in an induction phase and received 6-8 cycles of obinutuzumab, combined with 6 or 8 cycles of standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone/methylprednisolone \[CHOP - 21-day cycle) or bendamustine (28-day cycle), or cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone \[CVP - 21-day cycle\]). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. The investigator was free to choose the chemotherapy for each participant. | 113 |
| Total | 113 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Follow-up Phase | Adverse Event | 0 | 0 | 2 |
| Follow-up Phase | Death | 0 | 0 | 1 |
| Follow-up Phase | Progressive Disease | 0 | 0 | 3 |
| Follow-up Phase | Withdrawal by Subject | 0 | 0 | 1 |
| Induction Phase | Adverse Event | 5 | 0 | 0 |
| Induction Phase | Measures due to covid19; transformation to double hit high-grade b lymphoma; discontinuation of trt. | 3 | 0 | 0 |
| Induction Phase | Physician Decision | 2 | 0 | 0 |
| Induction Phase | Progressive Disease | 6 | 0 | 0 |
| Induction Phase | Withdrawal by Subject | 4 | 0 | 0 |
| Maintenance Phase | Adverse Event | 0 | 8 | 0 |
| Maintenance Phase | Death | 0 | 5 | 0 |
| Maintenance Phase | Physician Decision | 0 | 1 | 0 |
| Maintenance Phase | Progressive Disease | 0 | 7 | 0 |
| Maintenance Phase | Protocol Deviation | 0 | 1 | 0 |
| Maintenance Phase | Various reasons | 0 | 4 | 0 |
| Maintenance Phase | Withdrawal by Subject | 0 | 2 | 0 |
Baseline characteristics
| Characteristic | All Participants |
|---|---|
| Age, Continuous | 58.9 Years STANDARD_DEVIATION 12.7 |
| Race/Ethnicity, Customized Asian | 27 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 33 Participants |
| Race/Ethnicity, Customized Multiple | 2 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 80 Participants |
| Race/Ethnicity, Customized Other | 2 Participants |
| Race/Ethnicity, Customized White | 82 Participants |
| Sex: Female, Male Female | 56 Participants |
| Sex: Female, Male Male | 57 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 9 / 113 | 8 / 95 | 4 / 99 |
| other Total, other adverse events | 111 / 113 | 76 / 95 | 13 / 99 |
| serious Total, serious adverse events | 21 / 113 | 17 / 95 | 11 / 99 |
Outcome results
Primary
Percentage of Grade >=3 Infusion-Related Reactions (IRRs) During Cycle 2 in Patients Who Had Previously Received Obinutuzumab at the Standard Infusion Rate During Cycle 1 Without Experiencing a Grade 3 or 4 IRR
IRRs were defined as all adverse events (AEs) that occurred during or within 24 hours from the end of study treatment infusion and were judged as related to infusion of study treatment components by the investigator.
Time frame: Within 24 hours from the end of study treatment infusion of Day 1 in Cycle 2 (1 cycle: 21 or 28 days depending on the chemotherapy selected)
Population: The Short Duration Infusion (SDI) population included all enrolled particpants who did not experience a Grade 3 or 4 IRR during cycle 1 (i.e. at any of the three Cycle 1 infusions), received obinutuzumab given at the standard rate only during Cycle 1, and received obinutuzumab as an SDI at cycle 2.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Participants | Percentage of Grade >=3 Infusion-Related Reactions (IRRs) During Cycle 2 in Patients Who Had Previously Received Obinutuzumab at the Standard Infusion Rate During Cycle 1 Without Experiencing a Grade 3 or 4 IRR | 0 Percentage of Participants |
Secondary
Complete Response (CR) Rate at 30 Months (CR30), as Assessed by the Investigator and According to the Guidelines Used at the Site
The CR30 rate was defined as the percentage of participants with a CR at 30 months from study treatment initiation (date of first intake of any study treatment component), as determined by the investigator according to the guidelines used at the site.
Time frame: Baseline up to 30 months
Population: The safety population included all participants who received at least one dose of obinutuzumab.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Participants | Complete Response (CR) Rate at 30 Months (CR30), as Assessed by the Investigator and According to the Guidelines Used at the Site | 55.6 Percentage of Participants |
Secondary
Duration (In Minutes) of Obinutuzumab Administration by Cycle
The duration of obinutuzumab administration (in minutes) by cycle was defined as the difference between the end time and the start time of obinutuzumab administration.
Time frame: All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years)
Population: The safety population included all participants who received at least one dose of obinutuzumab.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | Cycle(C) 1 Day(D) 1 | 295.96 Minutes | Standard Deviation 147.87 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | C1D8 | 215.97 Minutes | Standard Deviation 46.99 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | C1D15 | 208.91 Minutes | Standard Deviation 33.13 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | C2 | 99.61 Minutes | Standard Deviation 13.36 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | C3 | 103.29 Minutes | Standard Deviation 65.45 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | C4 | 99.26 Minutes | Standard Deviation 13.9 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | C5 | 98.46 Minutes | Standard Deviation 16.48 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | C6 | 99.10 Minutes | Standard Deviation 12.18 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | C7 | 98.84 Minutes | Standard Deviation 13.61 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | C8 | 95.68 Minutes | Standard Deviation 4.12 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | Maintenance Week 1 | 97.64 Minutes | Standard Deviation 10.08 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | Maintenance Week 9 | 96.78 Minutes | Standard Deviation 8.49 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | Maintenance Week 17 | 97.77 Minutes | Standard Deviation 7.66 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | Maintenance Week 25 | 97.16 Minutes | Standard Deviation 7.23 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | Maintenance Week 33 | 95.08 Minutes | Standard Deviation 4.27 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | Maintenance Week 41 | 95.77 Minutes | Standard Deviation 5.26 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | Maintenance Week 49 | 93.56 Minutes | Standard Deviation 4.48 |
| All Participants | Duration (In Minutes) of Obinutuzumab Administration by Cycle | Maintenance Week 57 | 93.50 Minutes | Standard Deviation 4.95 |
Secondary
Duration of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle
The duration, in minutes, of IRRs during all cycles, where obinutuzumab was administered as an SDI.
Time frame: All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years)
Population: The safety population (113 participants) included all participants who received at least one dose of obinutuzumab.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| All Participants | Duration of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle | 165.0 Minutes |
Secondary
Objective Response Rate (ORR) at the End of Induction (EOI) Therapy
ORR at EOI therapy was defined as the percentage of particpants with either a CR, CR unconfirmed or PR at the EOI visit, as determined by the investigator and according to the guidelines used at the site.
Time frame: Baseline up to end of induction therapy (up to approximately 6 months)
Population: The safety population included all participants who received at least one dose of obinutuzumab.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| All Participants | Objective Response Rate (ORR) at the End of Induction (EOI) Therapy | Complete Response | 68.1 Percentage of Participants |
| All Participants | Objective Response Rate (ORR) at the End of Induction (EOI) Therapy | Partial Response | 19.5 Percentage of Participants |
Secondary
Overall Survival (OS) at the End of the Study
OS was defined as the time from start of treatment (date of first intake of any study treatment component) to death from any cause.
Time frame: Baseline up to end of study (up to approximately 4 years)
Population: The safety population included all participants who received at least one dose of obinutuzumab.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| All Participants | Overall Survival (OS) at the End of the Study | NA Months |
Secondary
Percentage of IRRs Regardless of Grade by Cycle
IRRs were defined as all adverse events (AEs) that occurred during or within 24 hours from the end of study treatment infusion and were judged as related to infusion of study treatment components by the investigator.
Time frame: Within 24 hours from the end of study treatment infusion in all cycles, including maintenance ((1 cycle: 21 or 28 days depending on the chemotherapy selected); up to approximately 2.5 years)
Population: The safety population included all participants who received at least one dose of obinutuzumab.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| All Participants | Percentage of IRRs Regardless of Grade by Cycle | Cycle 1 Day 1 | 50.4 Percentage of Participants |
| All Participants | Percentage of IRRs Regardless of Grade by Cycle | Cycle 1 Day 2 | 7.8 Percentage of Participants |
| All Participants | Percentage of IRRs Regardless of Grade by Cycle | Cycle 1 Day 8 | 5.4 Percentage of Participants |
| All Participants | Percentage of IRRs Regardless of Grade by Cycle | Cycle 1 Day 15 | 4.5 Percentage of Participants |
| All Participants | Percentage of IRRs Regardless of Grade by Cycle | Cycle 2 | 11.8 Percentage of Participants |
| All Participants | Percentage of IRRs Regardless of Grade by Cycle | Cycle 3 | 8.3 Percentage of Participants |
| All Participants | Percentage of IRRs Regardless of Grade by Cycle | Cycle 4 | 6.5 Percentage of Participants |
| All Participants | Percentage of IRRs Regardless of Grade by Cycle | Cycle 5 | 5.6 Percentage of Participants |
| All Participants | Percentage of IRRs Regardless of Grade by Cycle | Cycle 6 | 4.8 Percentage of Participants |
| All Participants | Percentage of IRRs Regardless of Grade by Cycle | Cycle 7 | 3.6 Percentage of Participants |
Secondary
Percentage of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a clinical investigation participant who was administered a pharmaceutical product, regardless of causal attribution. An AE was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study, recurrence of an intermittent medical condition, deterioration in a laboratory value or other clinical test or were related to a protocol-mandated intervention were also considered AEs. Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.
Time frame: Baseline up to end of study (approximately 4 years)
Population: The safety population included all participants who received at least one dose of obinutuzumab.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Participants | Percentage of Participants With Adverse Events (AEs) | 99.1 Percentage of Participants |
| Maintenance: Obinutuzumab | Percentage of Participants With Adverse Events (AEs) | 90.5 Percentage of Participants |
| Follow-up | Percentage of Participants With Adverse Events (AEs) | 27.3 Percentage of Participants |
Secondary
Progression-Free Survival (PFS) Rate at the End of the Study
PFS was defined as the time from start of treatment to the first occurrence of disease progression as assessed by the investigator according to the guidelines used at the site or death from any cause.
Time frame: Baseline up to end of study (up to approximately 4 years)
Population: The safety population included all participants who received at least one dose of obinutuzumab.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| All Participants | Progression-Free Survival (PFS) Rate at the End of the Study | 33.97 Months |
Secondary
Time to IRR From Infusion to Onset of the IRR During Cycle 2
Time to IRR (of any grade) in Cycle 2 was defined as the time from the start of infusion (i.e., start date/time of infusion of the first component of study treatment) in Cycle 2 to the onset of the IRR (of any grade) during Cycle 2.
Time frame: From infusion to onset of IRR during Cycle 2 (1 cycle: 21 or 28 days depending on the chemotherapy selected)
Population: The SDI population included all enrolled participants who did not experience a Grade 3 or 4 IRR during cycle 1 (i.e. at any of the three Cycle 1 infusions), received obinutuzumab given at the standard rate only during Cycle 1, and received obinutuzumab as an SDI at cycle 2. For this outcome measure, only one participant was analyzed.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| All Participants | Time to IRR From Infusion to Onset of the IRR During Cycle 2 | 11.800 Hours |
Secondary
Type of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle
Time frame: All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years)
Population: The safety population included all participants who received at least one dose of obinutuzumab. Only 1 participant had a Grade \>=3 IRR, with 3 symptoms in Cycle 5. Weight increased was a grade 1 symptom belonging to the grade 3 IRRs.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| All Participants | Type of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle | Cycle (C) 5- Hypertension | 33.3 Percentage of Participants |
| All Participants | Type of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle | C5 - Renal failure | 33.3 Percentage of Participants |
| All Participants | Type of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle | C5 - Weight increased | 33.3 Percentage of Participants |